A medication typically used for treating diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RA), could also be used to prevent cardiovascular disease and major cardiovascular events, but a new study showed inequities in its use based on race, ethnicity, and socioeconomic status. Looking at four years of data, researchers from the Perelman School of Medicine at...
Tag: <span>Diabetes drug</span>
Post
Common diabetes drug not effective against early-stage breast cancer, researchers say
by Amanda Ferguson, University of Toronto Metformin 500mg tablets. Credit: public domain A widely used and inexpensive type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most common forms of the disease, according to new research. The study, which has yet...
Post
Diabetes drug slows kidney function decline
by American Society of Nephrology Credit: Pixabay/CC0 Public Domain Clinical trial data reveal that dapagliflozin— a sodium-glucose cotransporter 2 inhibitor prescribed to treat diabetes—reduces the rate of kidney function decline in patients with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2021 November 4–November 7. The DAPA-CKD trial randomized 4,304...
Post
Common diabetes drug shows promise as treatment for COVID-19 lung inflammation
by Scott Lafee, University of California – San Diego Metformin 500mg tablets. Credit: public domain Metformin is a widely prescribed blood sugar-lowering drug. It is often used as an early therapy (in combination with diet and lifestyle changes) for type 2 diabetes, which afflicts more than 34 million Americans. Metformin works by lowering glucose production in...
Post
Diabetes drug could protect against dangerous infection
EXPERIMENTAL BIOLOGY IMAGE: METFORMIN AND C. DIFFICILE CREDIT: SHAOHUA WANG, PHD, AND HARIOM YADAV, PHD Rockville, Md. (April 27, 2021)–Researchers from Wake Forest School of Medicine in North Carolina have demonstrated that a common diabetes drug inhibits the spread of Clostridioides difficile, or C. diff–a potentially life-threatening infection commonly acquired during hospital stays. The team will...
Post
Diabetes drug shows potential in fighting cancer
MASSACHUSETTS GENERAL HOSPITAL BOSTON – The anti-diabetic drug phenformin may prompt stronger cancer-fighting activities than its sister compound metformin, a finding that could have major implications for current and future clinical trials investigating both agents for their anti-cancer potential, according to researchers at Massachusetts General Hospital (MGH). In a review article in Trends in Cancer, the team presented...
Post
Nostrum expands recall of diabetes drug metformin after carcinogen concerns
Conner Mitchell Associate Editor Generic metformin has been a thorn in drugmakers’ sides for months after a probable human carcinogen was found in tested lots. Now, one of the companies is expanding its recall to another lot of the drug. Nostrum Laboratories out of Kansas City, MO voluntarily recalled one lot of metformin HCl extended release...
Post
Diabetes drug can treat and reverse heart failure and reduce
THE MOUNT SINAI HOSPITAL / MOUNT SINAI SCHOOL OF MEDICINE Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai. Their clinical trial showed that this medication can improve the heart’s size, shape, and function, leading...
Post
Novel diabetes drug candidate shows promising properties in human islets and mouse models
The drug candidate is a non-toxic small molecule that given orally effectively rescued mice from models of Type 1 and Type 2 diabetes UNIVERSITY OF ALABAMA AT BIRMINGHAM ANATH SHALEV FROM UNIVERSITY OF ALABAMA AT BIRMINGHAM view more CREDIT: UAB BIRMINGHAM, Ala. – The University of Alabama at Birmingham and Southern Research have discovered a...
Post
Chemist develops potential drug to treat type 2 diabetes without harsh side effects
Credit: Syracuse University Syracuse, N.Y. – Syracuse University chemistry professor Dr. Robert P. Doyle has developed a new drug lead to treat type 2 diabetes in millions of patients who are seeking to better control their blood sugar without the common side effects of nausea, vomiting, and in select cases, undesired weight loss. Doyle’s research...